Dosing & Uses
Dosage Forms & Strengths
rectal suspension
- Each 150mL-dose contains between 1x108 and 5x1010 colony forming units (CFU) per mL of fecal microbes, including >1x105 CFU/mL of Bacteroides
- Fecal matter suspended in polyethylene glycol (PEG) 3350 and 0.9% NaCl solution
Clostridioides difficile Infection
Indicated for prevention of recurrence of Clostridioides difficile infection (CDI) in individuals aged ≥18 years, following antibiotic treatment for recurrent CD
Administer 24-72 hr after last dose of antibiotics for CDI
150 mL rectally as a single dose
Dosing Considerations
Limitation of use: Not indicated for treatment of CDI
Safety and efficacy not established
Adverse Effects
1-10%
Abdominal pain (8.9%)
Diarrhea (7.2%)
Abdominal distension (3.9%)
Flatulence (3.3%)
Nausea (3.3%)
Warnings
Contraindications
History of severe allergic reaction (eg, anaphylaxis) to any of the known product components
Cautions
Patients should notify physician if persistent diarrhea, defined as 3 or more loose bowel movements within a 24-hr period for 2 consecutive days, returns following product administration
Instruct patients not to take any oral antibiotic therapy for up to 8 weeks after product administration unless directed by their physician
Transmissible infectious agents
- Suspension may carry risk of transmitting infection since it is manufactured from human fecal matter
- Any infection suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Ferring Pharmaceuticals Inc
Acute allergic reaction
- Administer in facility where appropriate medical treatment is immediately available in event of acute anaphylactic reaction
Food allergens
- Manufactured from human fecal matter and may contain food allergens
- Potential for microbiota to cause adverse reactions due to food allergens is unknown
Pregnancy & Lactation
Pregnancy
Not absorbed systemically following rectal administration, and maternal use is not expected to result in fetal exposure
Lactation
Not absorbed systemically by the mother following rectal administration, and breastfeeding is not expected to result in exposure of the child
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Microbiota-based live biotherapeutic is delivered rectally to provide a broad consortium of diverse microbes to the gut to reduce recurrent C difficile infection after antibiotic treatment
Mechanism of action not established
Administration
Preparation
Prior to use, thaw completely by placing carton in refrigerator at 2-8ºC (36-46ºF) for ~24 hr; do not refreeze after thawing
Carton may be stored in refrigerator at 2-8ºC (36-46ºF) and used within 5 days, including thawing time
DO NOT thaw using a heat source (eg, microwave, hot water)
Condensation is normal after thawing
Remove thawed carton from refrigerator, then remove the bag containing thawed microbiota from outer carton and the inner carton insert
DO NOT remove the bag containing thawed microbiota from the sealed outer bag
Locate an administration set (supplied), water-soluble lubricant (not included), and disposable underpad (not included)
See prescribing information for complete instructions for setting up bag for administration
Rectal Administration
For rectal administration only
Prepare patient for administration by requesting they empty their bladder and bowel, if possible
Position patient in left-side position or knee-chest position for rectal administration
Apply water-soluble lubricant to administration tube tip; gently insert administration tube tip into rectum ~12 cm (5 inches) in a direction pointed slightly toward the umbilicus
Hold administration tube in place with 1 hand for the entire procedure to maintain the tube position in the rectum; with the other hand, open the pinch clamp on administration tube, and then gradually raise the bag to allow delivery via gravity flow
Do not allow administration tube to sag or loop, as this will prevent the entire dose from being delivered
Do not squeeze the bag as this may cause patient discomfort
Do not hang bag from IV stand
When entire dose has been delivered, close pinch clamp and then slowly withdraw the tube; take care to prevent any residual suspension remaining in tube from leaking out (some suspension will remain in tube after administration)
Once entire dose has been delivered, keep patient in position for up to 15 minutes to minimize any cramping that may occur
Dispose of all components for administration in medical waste
Storage
Contains live microorganisms; follow storage requirements carefully
Unopened carton
- Store in ultracold freezer (-60ºC to -90ºC [-76ºF to -130ºF)
- Alternatively, store refrigerated at 2-8ºC (36-46ºF) for up to 5 days (including thaw time)
- Do not refreeze after thawing
Administration set
- Store at 10-34ºC (50-93ºF)
- DO NOT store administration set in the freezer
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.